A Phase 2/3 interventional study of fecal microbial transplantation in Parkinson Disease, sponsored by Soroka University Medical Center. Completed at 1 site in Israel. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-05.
Sponsored by Soroka University Medical Center · Phase 2/3, Interventional, and Treatment
this pilot study aims to further explore the potential usage of Fecal microbiota transplantation in treating constipation and possibly also motor symptoms in Parkinson's disease (PD) patients, and to increase understanding of the potential relationship between the identities of intestinal microbial communities and PD.
Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms and Gastrointestinal dysfunction, in particular constipation, affects up to 80% of PD patients and may precede the onset of motor symptoms by years.
this study include one group of PD patients that will receive FMT. two other groups will serve as controls:
4,488 studies on the registry are indexed under Parkinson Disease; 1,083 are open to participants now.
This study's enrollment of 10 is below the median of 40 across 3,295 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Soroka University Medical Center is the lead sponsor of 157 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
fecal microbial transplantation once at the beginning of the study-15 patients.
Procedure: fecal microbial transplantation
do not receive treatment-35 patients.
do not receive treatment-50 participants.
Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
motor parkinsonian symptoms
motor symptoms assessed by UPDRS III questionaire
Time frame: Change from baseline motor difficulties at 6 months
constipation level
constipation will be assessed by a scoring system questionaire. 6 parameters are reviewed as scored fro 0 (mild symptom) to 4 (srvere symptom).
Time frame: Change from baseline constipation level at 6 months
Plan to share: Undecided
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Soroka University Medical Center